Login to Your Account



Oncolytics' Phase III Borrows Adaptive Design in SPA Trial

By By Catherine Hollingsworth


Monday, October 5, 2009
Oncolytics Biotech Inc. reached agreement with the FDA on the design of a Phase III trial of Reolysin in head and neck cancer, marking the first such agreement for an intravenously administered oncolytic virus. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription